Cited by 662Liver Disease Diagnosis and TreatmentDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Kuchay, Mohammad Shafi, Krishan, Sonal, Mishra, Sunil Kumar, Farooqui, Khalid Jamal, Singh, Manish Kumar, Wasir, Jasjeet Singh, Bansal, Beena, Kaur, Parjeet, Jevalikar, Ganesh, Gill, Harmendeep Kaur, Choudhary, Narendra Singh, Mithal, Ambrish·2018·Diabetes Care

DOI 10.2337/dc18-0165

Open this paper in CoChat — free account

Abstract

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have been shown to reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human liver fat are scarce. This study examined the effect of empagliflozin (an SGLT-2 inhibitor) on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) by using MRI-derived proton density fat fraction (MRI-PDFF). RESEARCH DESIGN AND METHODS Fifty patients with type 2 diabetes and NAFLD were randomly assigned to either the empagliflozin group (standard treatment for type 2 diabetes plus empagliflozin 10 mg daily) or the control group (standard treatment without empagliflozin) for 20 weeks. Change in liver fat was measured by MRI-PDFF. Secondary outcome measures were change in alanine transaminase (ALT), aspartate transaminase (AST), and γ-glutamyl transferase (GGT) levels. RESULTS When included in the standard treatment for type 2 diabetes, empagliflozin was significantly better at reducing liver fat (mean MRI-PDFF difference between the empagliflozin and control groups −4.0%; P < 0.0001). Compared with baseline, significant reduction was found in the end-of-treatment MRI-PDFF for the empagliflozin group (16.2% to 11.3%; P < 0.0001) and a nonsignificant change was found in the control group (16.4% to 15.5%; P = 0.057). The two groups showed a significant difference for change in serum ALT level (P = 0.005) and nonsignificant differences for AST (P = 0.212) and GGT (P = 0.057) levels. CONCLUSIONS When included in the standard treatment for type 2 diabetes, empagliflozin reduces liver fat and improves ALT levels in patients with type 2 diabetes and NAFLD.

Integrity signals

Registry

Crossref · 10.2337/dc18-0165

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values
MOFRAD, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,199

Show all 40 references

Sorted by citations

Items 401–500 of 657

Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 8
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
Salah, H. M., & Fudim, M. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.011 · Cited by 6
Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study
Kim, J., Han, K., Kim, B., Baek, K., Song, K., Kim, M. K., & Kwon, H. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110187 · Cited by 6
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Lee, H. A., Lee, H. A., & Kim, H. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79428-6 · Cited by 7
The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
Salmen, T., BOBIRCA, F. T., Bica, I.-C., Mihai, D. A., Pop, C. S., & Stoian, A. P. (2023) · Life · doi:10.3390/life13030839 · Cited by 8
An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials
Alfayez, A. I., Alfallaj, J. M., Mobark, M. A., Alalwan, A. A., & Alfayez, O. M. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230525150437 · Cited by 7
Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk
Dobbie, L. J., Cuthbertson, D. J., Hydes, T., Alam, U., & Zhao, S. S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad068 · Cited by 6
Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
Jung, C., Park, S., & Kim, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294423 · Cited by 6
Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
Bañares, J., Manzano-Núñez, R., Prio, A., Rivera‐Esteban, J., Camps-Relats, L., Villarejo, A., Ruiz‐Ortega, L., Pons, M., Ciudin, A., Salcedo, M. T., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.945626 · Cited by 6
Comparative efficacy of sodium-glucose transporter 2 inhibitors on lipid profiles in nonalcoholic fatty liver disease (NAFLD): a comprehensive Bayesian network meta-analysis
Khalil, I., Hossain, M. I., Akter, M., & Al‐Badri, S. G. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003658 · Cited by 5
Chemoprevention of hepatocellular carcinoma
Schwenk, S., & Kaplan, D. E. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000836 · Cited by 6
The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review
Popoviciu, M. S., Păduraru, L., Rahman, M., Supti, F. A., Stoica, R. A., Reurean‐Pintilei, D., Bica, C. I., & Cavalu, S. D. (2024) · Journal of Mind and Medical Sciences · doi:10.22543/2392-7674.1439 · Cited by 7
The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease
Ao, N., Du, J., Jin, S., Suo, L., & Yang, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16043 · Cited by 7
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 6
Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s392051 · Cited by 5
Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
Arriola‐Montenegro, J., Beas, R., Cerna-Viacava, R., Chapoñan-Lavalle, A., Randich, K. H., Chambergo‐Michilot, D., Sanga, H. F., & Mutirangura, P. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i7.328 · Cited by 5
Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
Lv, T.-S., Lou, Y., Yan, Q., Nie, L., Cheng, Z., & Zhou, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02037-9 · Cited by 6
Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
Procyk, G., Jaworski, J., Gąsecka, A., Filipiak, K. J., & Borovac, J. A. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.09.001 · Cited by 7
Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin
Miyazaki, R., Miyagi, K., & Yoshida, M. (2020) · Renal Replacement Therapy · doi:10.1186/s41100-020-00303-x · Cited by 5
The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
Yanai, H., Hakoshima, M., & Katsuyama, H. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4019 · Cited by 5
Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV
Guiraud, V., Sauce, D., Bittar, R., Fernández, J., Thévenet, H., Teyssou, E., Alkouri, R., Bonnefont‐Rousselot, D., Marcelin, A., Cálvez, V., et al. (2025) · Infectious Diseases Now · doi:10.1016/j.idnow.2025.105040 · Cited by 4
The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 7
The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Cabrera-Angeles, J. C., Hernández-Alba, A. L., García‐Arroyo, F. E., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Aparicio‐Trejo, O. E., del Valle‐Mondragón, L., Martínez-Olivares, C. E., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189010 · Cited by 4
Comparison of the efficacy of antidiabetic agents in type 2 diabetes with MASLD: a network meta-analysis
Shao, X., You, J., Zhang, H., & Jiang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1659740 · Cited by 4
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
Naumova, A. V., Cunha, G. M., Kim, N. J., Lu, J., Isquith, D. A., Chu, B., Maynard, C. C., Mahdavi, A., Firoozeh, N., Ordovas, K. G., et al. (2026) · Obesity · doi:10.1002/oby.70134 · Cited by 4
Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms and Clinical Implications—A Narrative Review
Fuentes-Barría, H., Aguilera-Eguía, R. A., Alarcón-Rivera, M., Angarita, L., & Flores-Fernández, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062532 · Cited by 4
Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines
Várkonyi, T. T., Kupai, K., Kang, H. L., Matusovits, D., Priksz, D., Várkonyi, Á., Lengyel, C., & Pósa, A. (2026) · Antioxidants · doi:10.3390/antiox15050553 · Cited by 4
Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH
Sobhia, M. E., Kumari, S., Kumar, H., Gandhe, A., Kaushik, D., Kumar, H., Jain, J., Ankita, A., Mallick, M., Pavani, B., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230714113808 · Cited by 4
Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta‐analysis
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging
Suzuki, A., Hayashi, A., Oda, S., Fujishima, R., Shimizu, N., Matoba, K., Taguchi, T., Toki, T., & Miyatsuka, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0005 · Cited by 4
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
Yadav, M. C., Verma, S., Tiwari, P., & Mugale, M. N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122934 · Cited by 4
Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 4
Acteoside inhibits hepatic lipid accumulation and oxidative stress in type 2 diabetic mice via the Nrf2/HO-1 Pathway
Hao, D., Zhang, L., Liu, S.-L., Sun, Z.-J., Si, R.-G.-L., Zhang, F., Yang, L., Jia, X., Li, T., Ai, L., et al. (2025) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2025.2473558 · Cited by 4
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
Bai, J., Zhang, L., He, L., & Zhou, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1613640 · Cited by 6
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 4
Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus
Koullias, E., Papavdi, M., Athanasopoulos, S., Mitrakou, A., Deutsch, M. J., Zoumpoulis, P. S., Manesis, E. K., Thanopoulou, A. C., & Koskinas, J. S. (2024) · Cureus · doi:10.7759/cureus.53813 · Cited by 4
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 5
Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer
Kajitani, N., Takahashi, J., Honda, H., Hamahara, J., & Ando, S. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4653-20 · Cited by 5
Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus
Gameil, M. A., Abdelgawad, M., Bahgat, M., El-Sebaie, A. H., & Marzouk, R. E. (2020) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-020-00013-0 · Cited by 5
New Medications for the Treatment of Diabetes
Garg, S. K., BRACKETT, S. J., Reinicke, T., & Hirsch, I. B. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2512 · Cited by 5
Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Guo, N., Shi, H., Zhang, H., & Wang, H. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03561-w · Cited by 4
Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review
Demidova, T. Y., & Омариевна, У. Ф. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202435 · Cited by 4
Integrative insights into cerebrometabolic disease: Understanding, management, and future prospects
Yan, G., Zhang, X., Liu, Y., Guo, P., Liu, Y., Li, X., Yong, V. W., & Xue, M. (2024) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2024.100107 · Cited by 6
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Mordi, I. R., & Lang, C. C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.004 · Cited by 5
Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism
Zheng, S., Huang, H., Chen, H., & Liu, Y. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04505-x · Cited by 4
Non-alcoholic Fatty Liver Disease
Kim, S. F., & Choi, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_36 · Cited by 4
Metabolic‐Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies
Cooper, J., Patel, P., Tristeza, J., & Yang, A. (2025) · International Journal of Hepatology · doi:10.1155/ijh/5580454 · Cited by 3
Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial
Taha, B. O., Kobeisy, M. A., Abdelmohsen, E., Abdelrhman, T. M., Abokresha, M. M., Hassanein, Z. M., & AbdEllah-Alawi, M. H. (2025) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2025.07.008 · Cited by 3
Beyond the Cardio–Renal–Metabolic Axis: Emerging Therapeutic Targets and Novel Mechanisms of Action of Flozins
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 3
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Evaluating the Comparative Effectiveness of Sodium-Glucose Transporter 2 Inhibitors (SGLT-2i) on Liver Enzymes in Patients With Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials
Khalil, I., Hossain, M. I., & Akter, M. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.08.007 · Cited by 3
Empagliflozin and its impact on hepatic and metabolic outcomes in patients with type 2 diabetes and NAFLD: a systematic review and meta-analysis
Hamzah, K. A., Shweliya, M. A., Kurmasha, Y. H., Ahmed, M. J., Habib, A., Kamel, A. I. I., Rashid, Z., Shimal, A. A., Moghazy, M., Fahem, F., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02084-x · Cited by 3
The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review
Laurence, A., Gandhi, S., Nylén, E., & Sen, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.011 · Cited by 3
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 4
The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
Qasim, A., Alataa, R., Veena, F., & Shehi, E. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1850915 · Cited by 3
How far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects
Omari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials—A Short Review
Kitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 3
Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Differential Effects of SGLT-2 Inhibitors on Liver Function and Nocturia in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Kawahara, T., Toda, M., Kanagawa, M., Toyama, N., Suzuki, G., Kawahara, C., & Inazu, T. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s547088 · Cited by 3
Efficacy of sodium-glucose co-transporter 2 inhibitors in treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
Ahmed, S. H., Moeed, A., Waqar, E., Rizwan, S., Hasnain, N., Qamar, M. A., Fatima, K., & Minhas, A. M. K. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100437 · Cited by 3
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment
Arredouani, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106445 · Cited by 3
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities, and Management of Non-alcoholic Fatty Liver Disorder
Barazesh, M., Jalili, S., Akhzari, M., Faraji, F., & Khorramdin, E. (2023) · Current Drug Therapy · doi:10.2174/1574885518666230417111247 · Cited by 3
Obesity management for the pre–liver transplant and post–liver transplant patient
Ahlers, C. G., & Kappus, M. R. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000039 · Cited by 3
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Choudhuri, G., Shah, S., Kulkarni, A. V., Jagtap, N., Gaonkar, P. P., Desai, A. S., & Adhav, C. V. (2023) · Cureus · doi:10.7759/cureus.42852 · Cited by 4
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Kostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3
Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus
Liu, S., Su, K., Zhang, L., Liu, M., & Zhao, W.-X. (2020) · Medicine · doi:10.1097/md.0000000000021568 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
Chadwick, J., Berry, C., Carpenter, M. A., Gulati, G., Heck, S. L., Hinterberg, M., Holman, R. R., Lee, M. M. Y., Omland, T., Paterson, C., et al. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70077 · Cited by 3
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
Ko, Y., Hur, M. H., Park, Y., Park, J., Shin, H., Lee, Y. B., Cho, E. J., Lee, J., Yu, S. J., Yoon, J., et al. (2025) · Gut and Liver · doi:10.5009/gnl240616 · Cited by 2
Efficacy and safety of liraglutide in non‐alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta‐analysis
Kong, W., Fang, B., & Xing, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70301 · Cited by 2
Prevalence and clinical characteristics of concurrent chronic hepatitis B and fatty liver disease in China: a systematic review and meta-analysis
Huang, J., Zhou, S., Guo, C., Zhang, X., Zhao, S., Dai, L., Liu, Z., & Zhang, T. (2025) · BMC Public Health · doi:10.1186/s12889-025-25816-0 · Cited by 2
Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP ‐ ELM study
Miyamoto, M., Miya, A., Nakamura, A., Takahashi, Y., Yamauchi, Y., Yanagiya, S., Takase, T., Ono, M., Takahashi, K., Okada, K., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70245 · Cited by 2
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors
Falsetti, L., Tarquinio, N., Mucci, L., Santini, S., Guerrieri, E., Giovenali, L., Pierdomenico, G., Zaccone, V., Viticchi, G., & Moroncini, G. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04023-9 · Cited by 3
Cardiovascular outcome trials in type 2 diabetes: A critical analysis
Ashraf, H., & Ahmad, J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.09.001 · Cited by 2
Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs
Demidova, T. Y., Скуридина, Д. В., & Pervushina, E. S. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-17 · Cited by 2
Unlocking the Potential of Type 2 Diabetes Mellitus Remission
Sharma, P., & Chakole, S. V. (2023) · Cureus · doi:10.7759/cureus.48704 · Cited by 3
Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Graft Inflammation: An Unaddressed Pathogenic Link after Kidney Transplantation
Hernández, A. F., González-Rinne, A. M., Hernández‐Bustabad, A., Guerra-Rodríguez, R., Saiz-Udaeta, A. P., Alonso-Titos, J., Marrero, D., Rivero-González, A. M., Quintana, C. A. S., Esteban, P. R., et al. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000543276 · Cited by 2
Comprehensive treatment with dapagliflozin in elderly chronic kidney disease patients: Clinical efficacy and impact on body composition
Nomura, K., Takata, T., Muramae, N., Takahashi, H., Abe, K., & Matsuda, T. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108951 · Cited by 2
Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐ STEP / LT ): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI
Uchinuma, H., Matsushita, M., Tanahashi, M., Suganami, H., Utsunomiya, K., Kaku, K., & Tsuchiya, K. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14402 · Cited by 2
Digital Twin Technology for Management of Chronic Metabolic Disease
Mohamed, M., Thajudeen, M., Damodharan, S., Raza, J. A., Erukulapati, R. S., Joshi, S., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_32 · Cited by 2
METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
Dezan, M. G. F., de Oliveira, C. P. M. S., & Cotrim, H. P. (2025) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612025-117 · Cited by 2
Effect of sodium-dependent glucose cotransporter type 2 inhibitors on lipid metabolism in patients with diabetes mellitus (literature review)
Левчук, Н. І., Kovzun, O., Pushkarev, V. M., & Tronko, M. D. (2023) · JOURNAL OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE · doi:10.37621/jnamsu-2023-1-2-1 · Cited by 2
Pre, peri and posttransplant diabetes mellitus
Essawy, B. E., & KANDEEL, F. R. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000469 · Cited by 2
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Brodosi, L., Musio, A., Barbanti, F. A., Mita, D., Marchesini, G., & Petroni, M. L. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.88 · Cited by 2
Association of insulin resistance and non-alcoholic fatty liver disease
Mishina, E. Е., Mayorov, A. Y., Bogomolov, P., Liusina, E. O., & Bueverov, A. O. (2021) · Diabetes Mellitus · doi:10.14341/dm12234 · Cited by 2
Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
Benjamin, S., Ramanjaneya, M., Butler, A. E., Janjua, I., Paramba, F., Palaki, J. A., Alkubaisi, A., Chandra, P., Abdalhakam, I., & Massodi, N. A. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.733693 · Cited by 2
Doença hepática gordurosa metabólica (DHGM)
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., de Araújo-Neto, J. M., Giacaglia, L. R., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-21 · Cited by 4
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Кедик, А. В., & Kutsin, O. O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-4-42 · Cited by 2
Effectiveness of One-Year Pemafibrate Therapy on Non-Alcoholic Fatty Liver Disease Refractory to Long-Term Sodium Glucose Cotransporter-2 Inhibitor Therapy: A Pilot Study
Shinozaki, S., Tahara, T., Miura, K., Lefor, A. K., & Yamamoto, H. (2023) · Life · doi:10.3390/life13061327 · Cited by 2
Could the answer to NAFLD be hidden in diabetic therapy? The impact of T2DM treatment on NAFLD
Shah, V., Colletti, T. P., & Reau, N. S. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000100 · Cited by 2
SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus
Ahmad, M. M., Brema, I. A., & Almalki, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84152 · Cited by 2
INIBIDORES DO COTRANSPORTADOR DE SÓDIO E GLICOSE DO TIPO 2: EFEITOS ALÉM DA GLICOSÚRIA
da Silva, D. G., Rodrigues, B. F. B., Brito, J. D. S., Afonso, D. M., & Amato, A. A. (2015) · Brasília Médica · doi:10.5935/2236-5117.2015v52n3/4a05 · Cited by 2
A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
Bossi, A. C., Forloni, F., & Colombelli, P. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00943-6 · Cited by 2
Recent Perspectives for Combined Status of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD)
Bando, H. (2021) · Edelweiss Journal of Biomedical Research and Review · doi:10.33805/2690-2613.118 · Cited by 2

Authors: Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., Choudhary, N. S., & Mithal, A.
Affiliations: Medanta The Medicity (IN)
Corresponding author: Kuchay, Mohammad Shafi
ORCID: Kuchay, Mohammad Shafi
Mishra, Sunil Kumar
Singh, Manish Kumar
Bansal, Beena
Kaur, Parjeet
Jevalikar, Ganesh
Choudhary, Narendra Singh
Mithal, Ambrish
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2018-06-12
Volume: 41
Issue: 8
Pages: 1801-1808
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc18-0165
OpenAlex: W2808615577
Cited by: 662
References: 40
Citations by year: 2026: 81 · 2025: 98 · 2024: 73 · 2023: 86 · 2022: 85 · 2021: 78 · 2020: 88 · 2019: 52 · 2018: 18
FWCI: 46.08
Type: journal article
Language: en
Open access: closed
Licence: www.diabetesjournals.org/content/license (vor, 38 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Endocrine and Diabetes Foundation, India
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: empagliflozin, SGLT2 inhibitors, liver fat, non-alcoholic fatty liver disease, type 2 diabetes, proton density fat fraction, alanine aminotransferase, liver enzymes
MeSH terms: Adipose Tissue, Adult, Alanine Transaminase, Aspartate Aminotransferases, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Treatment Outcome, Adiposity, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks